In this edition, lecanemab study shows reduction in clinical decline for early AD; multimorbidity associated with increased risk for dementia, Crenezumab not effective in treating Alzheimer's disease and more. Read the full coverage here: Phase 3 study of lecanemab shows reduction in clinical decline in patients with early AD Multimorbidity associated with increased risk for dementia Crenezumab not effective in treating Alzheimer's disease FDA approves macrocyclic GBCA for contrast-enhanced MRI Healthy habits in midlife may help delay onset of cognitive decline References: Calvin CM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.32124. Ostrowitzki S, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2909. Press Release Press Release Small G. What's preventing us from preventing dementia? Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.

Ver todos los episodios